Financial reports
ARS
2023 FY
Annual report to shareholders
12 Apr 24
10-K
2023 FY
Annual report
7 Mar 24
10-Q
2023 Q3
Quarterly report
14 Nov 23
10-Q
2023 Q2
Quarterly report
10 Aug 23
10-Q
2023 Q1
Quarterly report
11 May 23
ARS
2022 FY
Annual report to shareholders
28 Apr 23
10-K
2022 FY
Annual report
23 Mar 23
10-Q
2022 Q3
Quarterly report
10 Nov 22
10-Q
2022 Q2
Quarterly report
11 Aug 22
10-Q
2022 Q1
Quarterly report
10 May 22
Current reports
8-K
Werewolf Therapeutics Reports Fourth Quarter and Full Year 2023 Financial Results and Provides Business Update
7 Mar 24
8-K
Other Events
9 Feb 24
8-K
Werewolf Therapeutics Provides Business Update and Highlights 2024 Strategic Outlook
8 Jan 24
8-K
Departure of Directors or Certain Officers
4 Jan 24
8-K
Werewolf Therapeutics Reports Third Quarter 2023 Financial Results and Provides Business Update
14 Nov 23
8-K
Regulation FD Disclosure
3 Nov 23
8-K
Regulation FD Disclosure
18 Sep 23
8-K
Werewolf Therapeutics Reports Second Quarter 2023 Financial Results and Provides Business Update
10 Aug 23
8-K
Amendments to Articles of Incorporation or Bylaws
27 Jun 23
8-K
Werewolf Therapeutics Reports First Quarter 2023 Financial Results and Provides Business Update
11 May 23
Registration and prospectus
S-8
Registration of securities for employees
7 Mar 24
424B5
Prospectus supplement for primary offering
9 Feb 24
S-8
Registration of securities for employees
23 Mar 23
S-3
Shelf registration
10 May 22
S-8
Registration of securities for employees
24 Mar 22
424B4
Prospectus supplement with pricing info
30 Apr 21
S-8
Registration of securities for employees
30 Apr 21
S-1MEF
Registration of additional securities for an S-1
29 Apr 21
8-A12B
Registration of securities on exchange
27 Apr 21
S-1/A
IPO registration (amended)
26 Apr 21
Other
EFFECT
Notice of effectiveness
23 May 22
CORRESP
Correspondence with SEC
18 May 22
UPLOAD
Letter from SEC
13 May 22
EFFECT
Notice of effectiveness
30 Apr 21
CERT
Certification of approval for exchange listing
29 Apr 21
SEC STAFF
SEC staff action: Order
29 Apr 21
CORRESP
Correspondence with SEC
27 Apr 21
CORRESP
Correspondence with SEC
27 Apr 21
SEC STAFF
SEC staff action: Order
23 Apr 21
CORRESP
Correspondence with SEC
8 Apr 21
Ownership
SC 13D/A
RA CAPITAL MANAGEMENT, L.P.
14 Feb 24
SC 13G/A
PFM Health Sciences, LP
14 Feb 24
SC 13G
BANK OF AMERICA CORP /DE/
13 Feb 24
SC 13G/A
Rubric Capital Management LP
12 Feb 24
4
Michael B. Atkins
4 Jan 24
3
Michael B. Atkins
4 Jan 24
4
Timothy W. Trost
4 Jan 24
4
Ellen Lubman
4 Jan 24
4
Randi Isaacs
4 Jan 24
4
Chulani Karunatilake
4 Jan 24